Exhibits G protein-coupled receptor activity. Involved in positive regulation of ERK1 and ERK2 cascade and positive regulation of cholangiocyte proliferation. Predicted to localize to cytoplasm; plasma membrane; and receptor complex. Biomarker of non-alcoholic steatohepatitis and polycystic kidney disease. Orthologous to human GPBAR1 (G protein-coupled bile acid receptor 1); INTERACTS WITH ammonium chloride; beta-naphthoflavone; bisphenol A.
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP, [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GPBAR1 mRNA more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GPBAR1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of GPBAR1 mRNA
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium, [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium, [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium
[Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP, Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein
[Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP, Colforsin binds to and results in increased activity of GPBAR1 protein
[Flame Retardants co-treated with pentabromodiphenyl ether co-treated with decabromobiphenyl ether co-treated with hexabromocyclododecane] results in increased expression of GPBAR1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GPBAR1 mRNA more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GPBAR1 mRNA more ...
[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GPBAR1 mRNA, [indole-3-carbinol co-treated with Diethylnitrosamine co-treated with Acetylcysteine] results in decreased expression of GPBAR1 mRNA
[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Calcium, Oleanolic Acid binds to and results in increased activity of GPBAR1 protein
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
